Aravive Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Aravive.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs earnings growth | 28.4% |
Revenue growth rate | n/a |
Future return on equity | n/a |
Analyst coverage | None |
Last updated | n/a |
Recent future growth updates
Recent updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Apr 26Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Sep 03Aravive Q2 GAAP EPS misses, revenue beats
Aug 11Aravive appoints Robert Geller as CMO
Jul 05We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully
May 15Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Nov 06Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Jun 25Aravive EPS beats by $0.01, misses on revenue
May 06Aravive shares rise after dosing first patient in late-stage ovarian cancer study
Apr 27Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?
Mar 18Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Feb 09Aravive: Pipeline-In-A-Pill In Oncology
Dec 28Aravive (ARAV) Investor Presentation - Slideshow
Dec 04Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative
Nov 19Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China
Nov 10In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Aravive has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2023 | 7 | -40 | -59 | -59 | N/A |
6/30/2023 | 9 | -77 | -69 | -69 | N/A |
3/31/2023 | 10 | -113 | -70 | -70 | N/A |
12/31/2022 | 9 | -76 | -65 | -65 | N/A |
9/30/2022 | 9 | -60 | -59 | -59 | N/A |
6/30/2022 | 6 | -56 | -49 | -49 | N/A |
3/31/2022 | 8 | -44 | -35 | -35 | N/A |
12/31/2021 | 7 | -39 | -32 | -32 | N/A |
9/30/2021 | 12 | -30 | -20 | -20 | N/A |
6/30/2021 | 10 | -30 | -17 | -17 | N/A |
3/31/2021 | 6 | -28 | -18 | -18 | N/A |
12/31/2020 | 6 | -31 | -12 | -12 | N/A |
9/30/2020 | N/A | -31 | -21 | -21 | N/A |
6/30/2020 | N/A | -26 | -19 | -19 | N/A |
3/31/2020 | 3 | -24 | -20 | -20 | N/A |
12/31/2019 | 5 | -18 | -17 | -17 | N/A |
9/30/2019 | 6 | -65 | -21 | -21 | N/A |
6/30/2019 | 6 | -65 | -23 | -23 | N/A |
3/31/2019 | 3 | -72 | -23 | -23 | N/A |
12/31/2018 | 1 | -76 | -29 | -29 | N/A |
9/30/2018 | 40 | 6 | -58 | -57 | N/A |
6/30/2018 | 40 | -37 | -78 | -75 | N/A |
3/31/2018 | 40 | -64 | -94 | -90 | N/A |
12/31/2017 | 40 | -85 | -121 | -116 | N/A |
9/30/2017 | N/A | -138 | -101 | -98 | N/A |
6/30/2017 | N/A | -116 | N/A | -53 | N/A |
3/31/2017 | N/A | -101 | N/A | -54 | N/A |
12/31/2016 | N/A | -96 | N/A | -41 | N/A |
9/30/2016 | N/A | -94 | N/A | -38 | N/A |
6/30/2016 | N/A | -87 | N/A | -78 | N/A |
3/31/2016 | N/A | -84 | N/A | -70 | N/A |
12/31/2015 | N/A | -82 | N/A | -69 | N/A |
9/30/2015 | N/A | -78 | N/A | -64 | N/A |
6/30/2015 | N/A | -71 | N/A | -58 | N/A |
3/31/2015 | N/A | -60 | N/A | -54 | N/A |
12/31/2014 | N/A | -83 | N/A | -40 | N/A |
9/30/2014 | N/A | -73 | N/A | -33 | N/A |
6/30/2014 | N/A | -64 | N/A | -27 | N/A |
3/31/2014 | N/A | -59 | N/A | -18 | N/A |
12/31/2013 | N/A | -18 | N/A | -17 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ARAV's forecast earnings growth is above the savings rate (2.2%).
Earnings vs Market: Insufficient data to determine if ARAV's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if ARAV's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ARAV's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ARAV's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ARAV's Return on Equity is forecast to be high in 3 years time